Patents by Inventor Adnan M. M. Mjalli

Adnan M. M. Mjalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
    Patent number: 10064846
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: September 4, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 10030011
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: July 24, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20180071297
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 15, 2018
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
    Patent number: 9855251
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: January 2, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase Activator
    Publication number: 20170354647
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Application
    Filed: August 28, 2017
    Publication date: December 14, 2017
    Inventors: Adnan M.M. Mjalli, Maria Carmen Valcarce Lopez
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 9833457
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to psoriatic arthritis.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: December 5, 2017
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20170252343
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to psoriatic arthritis.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 7, 2017
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 9687489
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to psoriasis.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: June 27, 2017
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20160296526
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to psoriasis.
    Type: Application
    Filed: June 16, 2016
    Publication date: October 13, 2016
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
    Patent number: 9393245
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: July 19, 2016
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase Activator
    Publication number: 20160184277
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Application
    Filed: February 11, 2016
    Publication date: June 30, 2016
    Inventors: Adnan M.M. Mjalli, Maria Carmen Valcarce Lopez
  • Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
    Patent number: 9359313
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: June 7, 2016
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20150374700
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Combinations of a GLP1R Agonist and Metformin and Use Thereof for the Treatment of Type 2 Diabetes and Other Disorders
    Publication number: 20150313908
    Abstract: The present invention provides uses of a glucagon-like peptide 1 receptor agonist in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GLP1R agonist and metformin.
    Type: Application
    Filed: July 14, 2015
    Publication date: November 5, 2015
    Inventors: Adnan M.M. Mjalli, Bradley Alan Clark, Dharma Rao Polisetti, James C. Quada, JR., Maria Carmen Valcarce Lopez, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
  • Substituted azoanthracene derivatives and intermediates for preparation thereof
    Patent number: 9175003
    Abstract: The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 3, 2015
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, Jr., Jennifer L. R. Freeman, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Santhosh Kalpathy, Stephen Thomas Davis, Thomas Scott Yokum
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 9163022
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: October 20, 2015
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Oxadiazoanthracene compounds for the treatment of diabetes
    Patent number: 9120813
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: September 1, 2015
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Santhosh Kalpathy, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof
    Publication number: 20150148539
    Abstract: The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 28, 2015
    Inventors: Adnan M.M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, JR., Jennifer L.R. Freeman, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Santhosh Kalpathy, Stephen Thomas Davis, Thomas Scott Yokum
  • Oxadiazoanthracene Compounds for the Treatment of Diabetes
    Publication number: 20150087640
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Santhosh Kalpathy, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Aryl carbonyl derivatives as therapeutic agents
    Patent number: RE45670
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 15, 2015
    Assignee: NOVO NORDISK A/S
    Inventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper F. Lau, Paw Bloch, Mustafa Guzel, Santhosh Chidambareswaran Kalpathy, Adnan M. M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen, Jesper Lau